Janux Therapeutics JANX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's additional paid-in capital?
- Janux Therapeutics (JANX) reported additional paid-in capital of $1.32B in Q1 2026.
- How has Janux Therapeutics's additional paid-in capital changed year-over-year?
- Janux Therapeutics's additional paid-in capital increased by 3.7% year-over-year, from $1.27B to $1.32B.
- What is the long-term trend for Janux Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Janux Therapeutics's additional paid-in capital has grown at a 565.3% compound annual growth rate (CAGR), from $100K to $1.3B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.